Bumrungrad International Hospital’s VitalLife to launch NEC’s FonesVisuas Test in Thailand

It uses a small blood sample to predict risks for dementia, heart attack, lung cancer, and chronic kidney disease.

VitalLife Scientific Wellness Center, a subsidiary of Bumrungrad International Hospital in Bangkok, has partnered with NEC Corporation to introduce NEC’s FonesVisuas Test to the Thai market.

This advanced blood test, previously available only in Japan, marks its international debut at the VitalLife Scientific Wellness Center.

The FonesVisuas Test analyses daily-changing proteins from a small blood sample to predict risks for conditions such as dementia, heart attack, lung cancer, and chronic kidney disease over the next few years. 

The development aligns with global health trends, as noted by the World Health Organization (WHO) and OECD data, which highlight the growing prevalence of lifestyle-related diseases and the need for proactive health management.

Additonally, the new service complements VitalLife’s existing genetic testing offerings at Bumrungrad International Hospital, reinforcing its dedication to personalisJed health interventions and improving patient outcomes.